Sarepta Therapeutics Non-GAAP EPS of -$3.58 misses by $2.81, revenue of $443M beats by $52.05M
Source: SeekingAlpha
2026-02-25 16:14:57 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy - Slideshow
- Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
- Sarepta Preliminary Results: Not What The Market Wanted To Hear
- Sarepta Therapeutics Q4 2025 Earnings Preview
- Regenxbio dealt win by appeals court in patent spat with Sarepta
Read the full article on Seeking Alpha
For further details see:
Sarepta Therapeutics Non-GAAP EPS of -$3.58 misses by $2.81, revenue of $443M beats by $52.05M
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-4.03% G/L:
$17.165 Last:
1,202,704 Volume:
$17.54 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
